Terms: = Leukemia AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
8 results:
1. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract] [Full Text] [Related]
2. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
Choi JE; Kang SH; Lee SJ; Bae YK
Tumour Biol; 2014 Dec; 35(12):12255-63. PubMed ID: 25179840
[TBL] [Abstract] [Full Text] [Related]
4. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract] [Full Text] [Related]
5. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
[TBL] [Abstract] [Full Text] [Related]
6. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
[TBL] [Abstract] [Full Text] [Related]
7. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Ogino S; Meyerhardt JA; Irahara N; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Goldberg RM; Bertagnolli MM; Fuchs CS; ; ; ;
Clin Cancer Res; 2009 Dec; 15(23):7322-9. PubMed ID: 19934290
[TBL] [Abstract] [Full Text] [Related]
8. Targeted therapies in gynecologic cancers.
Chon HS; Hu W; Kavanagh JJ
Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
[TBL] [Abstract] [Full Text] [Related]
